Kenvue Inc.
- Industrie
- Household & Personal Care
- Bourse
- États-Unis
- Pays / Région
- USA
- Date d'introduction en bourse
- 4 mai 2023
- Effectif
- 21 780
- Site web
- www.kenvue.com
Fourchette de valorisation composite · prudent $10–$13 / raisonnable $16–$20 / optimiste $22–$26. À $18.12, Dans la fourchette de valeur intrinsèque raisonnable.
À la publication $17.69 (28 mai 2026)
Pas encore d'analyse sur cette valeur dans votre langue.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Historique
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Position dans le secteur
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
